Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2956
Abstract: OPTIC was a randomized, phase 2 dose-optimization trial of ponatinib in chronic phase-chronic myeloid leukemia (CP-CML) resistant to ≥2 tyrosine kinase inhibitors or with T315I mutation. Patients were randomized to starting doses of 45-, 30-,… read more here.
Keywords: ponatinib; response; dose increase; exposure ... See more keywords
Upfront low‐dose ponatinib (15 mg/day) for multi‐TKI resistant chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Hematological Oncology"
DOI: 10.1002/hon.2517
Abstract: There is currently little information on the upfront use of low‐dose ponatinib (15 mg once‐daily) for patients with chronic phase chronic myeloid leukemia. And yet, the concept carries immediate clinical relevance because of the association… read more here.
Keywords: low dose; myeloid leukemia; dose ponatinib; chronic myeloid ... See more keywords
Origanum Sipyleum Methanol Extract in Combination with Ponatinib Shows Synergistic anti-Leukemic Activities on Chronic Myeloid Leukemia Cells
Sign Up to like & getrecommendations! Published in 2022 at "Nutrition and Cancer"
DOI: 10.1080/01635581.2022.2077969
Abstract: Abstract Origanum sipyleum is used in folk medicine due to its anti-inflammatory, antimicrobial, and antioxidant properties. Ponatinib, an effective tyrosine kinase inhibitor in the treatment of chronic myeloid leukemia (CML), has severe side effects. Thus,… read more here.
Keywords: origanum sipyleum; combination; osm; ponatinib ... See more keywords
Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2022.2064742
Abstract: ABSTRACT Introduction Patients with chronic myeloid leukemia in chronic phase (CP-CML) who are resistant or intolerant to second-generation tyrosine kinase inhibitors (TKIs) may benefit from treatment with a third-generation TKI, like ponatinib. Areas covered In… read more here.
Keywords: myeloid leukemia; chronic myeloid; resistant intolerant; generation ... See more keywords
An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2077187
Abstract: ABSTRACT Introduction Chronic myeloid leukemia is now a highly treatable leukemia due to the availability of multiple tyrosine kinase inhibitors (TKIs) inhibiting the BCR-ABL1 oncogene. Some patients with CML can display resistance or intolerance to… read more here.
Keywords: patients resistant; myeloid leukemia; chronic myeloid; leukemia ... See more keywords
Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR
Sign Up to like & getrecommendations! Published in 2023 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00067-23
Abstract: Although antiretroviral therapy (ART) is effective in suppressing viral replication, it does not cure HIV-1 infection due to the presence of the viral latent reservoir. Rather than reactivating the latent viruses, the “block and lock”… read more here.
Keywords: latent hiv; hiv; reservoir; akt mtor ... See more keywords
Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors
Sign Up to like & getrecommendations! Published in 2019 at "Chemotherapy"
DOI: 10.1159/000504664
Abstract: Cardiovascular (CV) adverse events are considered common complications of ponatinib treatment. Recently, it has been demonstrated that ponatinib dose reductions in definite settings can obtain optimal responses and lower ponatinib-related CV events. In this study,… read more here.
Keywords: risk; myeloid leukemia; management; patients chronic ... See more keywords
Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation
Sign Up to like & getrecommendations! Published in 2023 at "Circulation Research"
DOI: 10.1161/circresaha.122.321504
Abstract: Background: The tyrosine kinase inhibitor ponatinib is the only treatment option for chronic myelogenous leukemia patients with T315I (gatekeeper) mutation. Pharmacovigilance analysis of Food and Drug Administration and World Health Organization datasets has revealed that… read more here.
Keywords: inflammation; ponatinib drives; drives cardiotoxicity; ponatinib ... See more keywords
Blinatumomab + Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-111546
Abstract: Prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1+ ALL) has been considerably improved since the beginning of the BCR-ABL1 tyrosine kinase inhibitors (TKI) era 20 years ago. However, the prognosis of patients with a refractory/relapsed… read more here.
Keywords: blina pona; blinatumomab; cycle; relapsed ph1 ... See more keywords
One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116825
Abstract: Background: Ponatinib is effective as salvage treatment for chronic phase (CP) Ph+ chronic myeloid leukemia (CML) patients resistant or intolerant to prior TKIs. Based on the concern for an unfavourable cardiovascular toxicity profile, a dose… read more here.
Keywords: cml patients; starting dose; treatment; honoraria ... See more keywords
Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-125052
Abstract: Background: Since its introduction ponatinib has proved great efficacy among patients (pts) with chronic myeloid leukemia (CML), representing in some settings like the T315I mutation the only therapeutical choice due to its unique conformation. Its… read more here.
Keywords: cml; use; pfizer; honoraria ... See more keywords